Deciphera Pharmaceuticals, Inc.

About Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals is dedicated to defeating cancer, inspired by patients. Their mission is to improve the lives of people living with cancer through innovative drug development and a commitment to patient communities.

Products & Services

Ripretinib:A drug candidate in Deciphera's pipeline targeting cancer treatment.

Vimseltinib (ROMVIMZA™):A treatment for tenosynovial giant cell tumor (TGCT), recently approved by the European Commission.

Sapablursen:A drug candidate with positive topline results from a Phase 2a study for Polycythemia Vera.

QINLOCK:A registered trademark drug for cancer treatment.

Specialties

Switch-control kinase inhibitors Cancer treatment drug development Tumor and drug resistance mechanisms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Financing T: - FT: Equity Financing	A: 143700000 MR: - FA: approximately $143.7 million FAN: 143700000	D: 2023-01-24 FD: 2023-01-24	4 investors
2	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 125000000 MR: - FA: $125 million FAN: 125000000	D: 2023-01-19 FD: 2023-01-19	4 investors
3	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 125000000 MR: - FA: $125,000,000 FAN: 125000000	D: 2023-01-18 FD: 2023-01-18	4 investors

Equity Financing Latest

2023-01-24

$143.7M

4 investors (Pro only)

Public Offering of Common Stock 2023-01-19

$125.0M

Public Offering of Common Stock 2023-01-18

$125.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ryota Udagawa

President and Chief Executive Officer

M

Margarida Duarte

Executive Vice President, Global Chief Commercial Officer

P

Peter Habura

Senior Vice President of Regulatory, Quality & Medical Writing

J

Jenn Larson

Senior Vice President, Chief Financial Officer

M

Maria Ostrovsky

Senior Vice President, General Counsel

M

Matthew L. Sherman, M.D.

Executive Vice President, Chief Medical Officer

View 4 more team members with Pro

Unlock Full Team Directory

Recent News